From Barrett's mucosa to adenocarcinoma. Can the dangers of natural history be overcome?;De l'endobrachyoesphage a l'adenocarcinome: peut-on dejouer les dangers d'une historie naturelle?

Gastroenterologie Clinique et Biologique

Volumn 20, Issue 5 BIS, 1996, Pages

  Robaszkiewicz, Michel ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Adenocarcinoma; Barrett's esophagus; DNA content flow cytometry; Dysplasia; p53; Surveillance

Indexed keywords

PROTEIN P53; TUMOR MARKER;

BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER SCREENING; CONFERENCE PAPER; DNA CONTENT; DYSPLASIA; ESOPHAGUS CARCINOMA; HUMAN; MALIGNANT TRANSFORMATION; METAPLASIA; PRACTICE GUIDELINE; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; ESOPHAGUS TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; TIME;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; HUMANS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029742654     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (111)

1. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986; 315: 362-71.
2. Potet F. Difficultés du diagnostic de muqueuse de Barrett. Les formes limites d'endobrachyœsophage. Gastroenterol Clin Biol 1994; 18(suppl 1): D13-D16.
3. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-3.
4. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-89.
5. Blot WJ, Devesa SS, Fraumeni JF. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 1993; 270: 1320.
6. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990; 62: 440-3.
7. Tuyns AJ. Œsophageal cancer in France and Switzerland: recent time trends. Eur J Cancer Prev 1992; 1: 275-8.
8. Moller H. Incidence of cancer of the esophagus, cardia and stomach in Denmark. Eur J Cancer Prev 1992; 1: 159-64.
9. Hansson LE, Sparen P, Nyren O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer 1993; 54: 402-7.
10. Iascone C, De Meester TR, Little Ag, Skinner DB. Barrett's esophagus: functionnal assessment, proposed pathogenesis and surgical therapy. Arch Surg 1983; 118: 543-9.
11. Winters C, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-24.
12. Mann NS, Tsai MF, Nair PK. Barrett's esophagus in patients with symptomatic reflux esophagitis. Am J Gastroenterol 1989; 84: 1494-6.
13. Johnson DA, Winters C, Spurling TJ, Chobanian SJ, Cattau ELJr. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987; 9: 23-7.
14. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99: 918-22.
15. Cameron AJ. Epidemiology of Barrett's esophagus. Gastroenterol Clin Biol 1994; 18 (suppl 1): D3-D4.
16. Freston JW, Malagelada JR, Petersen H, McCloy RF. Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 1995; 7: 577-86.
17. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence and extent of columnar epithelium. Gastroenterology 1992; 103: 1241-5.
18. Gruppo Operative per lo Studio delle Precancerosi dell' Esofago (GOSPE). Barrett's esophagus: epidemiological and clinical results of a multicentric survey. Int J Cancer 1991; 48: 364-8.
19. Sampliner RE, Garewal HS, Fennerty MB, Aickin M. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci 1990; 35: 93-6.
20. Spechler SJ, Robbins AH, Bloomfield-Rubins H, Vincent ME, Heeren T, Doos WG, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984; 87: 927-33.
21. Skinner DB, Walther BC, Riddell RH, Schmidt H, Iascone C, De Meester TR. Barrett's esophagus: comparison of benign and malignant cases. Ann Surg 1983; 198: 554-66.
22. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-9.
23. Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol 1988; 83: 291-4.
24. Williamson WA, Ellis FH, Gibb SP, Shahian DM, Aretz MT, Hetley GJ, et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991; 151: 2212-6.
25. Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's esophagus. Br J Surg 1988; 75: 760-3.
26. Van Der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett's œsophagus: an overrated risk. Gut 1989; 30: 14-8.
27. Hameetman W, Tytgat GNJ, Houthoff HJ, Van Den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-56.
28. Ovaska J, Miettinen M, Kivilaakso E. Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci 1989; 34: 1336-9.
29. Polepalle SC, McCallum RW. Barrett's esophagus. Current assessment and future perspectives. Gastroenterol Clin North Am 1990; 19: 733-44.
30. Schnell TG, Sontag SJ, Chejfec G. Adenocarcinomas arising in tongues or short segments of Barrett's esophagus. Dig Dis Sci 1992; 37: 137-43.
31. Potet F. Le cancer du cardia et le cancer sur endobrachyœsophage sont-ils des entités différentes? Gastroenterol Clin Biol 1994; 18(suppl 1): D56-D58.
32. Lomboy CT, Pera M, Cameron AJ, Carpenter HA, Trastek VF. Adenocarcinoma of the esophagus and espphagogastric junction are both associated with Barrett's epithelium (abstract). Gastroenterology 1992; 102: A373.
33. Clark GW, Smyrk TC, Burdiles P, Hoeft SF, Peters JH, Kiyabu M et al. Is Barrett's metaplasia the source of adenocarcinoma of the cardia? Arch Surg 1994; 129: 609-14.
34. Boyer J. Aspects cliniques et endoscopiques de l'endobrachyœsophage. Gastroenterol Clin Biol 1994; 18(suppl 1): D5-D11.
35. Levine DS, Reid BJ. Endoscopic biopsy technique for acquiring larger mucosal samples. Gastrointest Endosc 1991; 37: 332-7.
36. Tytgat GNJ, Hameetman W, Onstenk R, Schotborg R. The spectrum of columnar-lined esophagus - Barrett's esophagus. Endoscopy 1989; 21: 177-85.
37. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105: 40-50.
38. Paull A, Trier JS, Dalton MO, Camp RC, Loeb P, Goyal RK. The histological spectrum of Barrett's esophagus. N Engl J Med 1976; 295: 476-80.
39. Diebold MD. Muqueuse de Barrett et mucosécrétion: l'histochimie des mucines a-t-elle une valeur prédictive? Gastroenterol Clin Biol 1994; 18 (suppl 1): D29-D30.
40. Haggitt RC, Dean PJ. Adenocarcinoma in Barrett's epithelium. In: Spechler SJ, Goyal RK, eds. Barrett's œsophagus. Pathophysiology, diagnosis and management. New York: Elsevier Science, 1985: 153-66.
41. Thompson JJ, Zeinsser KR, Enterline HT. Barrett's metaplasia and adenocarcinoma of the esophagus and gastroesophageal junction. Hum Pathol 1983; 14: 42-61.
42. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994; 344: 1533-36.
43. Potet F, Barge J. La dysplasie dans le tube digestif. Ann Pathol 1991; 11: 153-61.
44. Diebold MD. Dysplasie et muqueuse de Barrett. Gastroenterol Clin Biol 1994; 18:D24-28.
45. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14: 931-68.
46. Mc Ardle JE, Lewin KJ, Randall G, Weinstein WM. Distribution of dysplasia and early invasive carcinoma in Barrett's esophagus. Hum Pathol 1992; 23: 479-82.
47. Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, Van Deventer G, Den Besten L, et al. Endoscopic biopsy can detect high grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognisable neoplastic lesion. Gastroenterology 1988; 94: 81-90.
48. Schmidt HG, Riddell RH, Walther B, Skinner DB, Riemann JF. Dysplasia in Barrett's esophagus. Cancer Res Clin Oncol 1985; 110: 145-52.
49. Herlihy KJ, Orlando RC, Bryson JC, Bozymski EM, Carney CN, Powell DW. Barrett's esophagus: clinical, endoscopic, histologic, manometric and electrical potential difference characteristics. Gastroenterology 1984; 86: 436-43.
50. Potet F, Duchatelle V. Barrett's esophagus. In: Williams GT ed. Gastrointestinal pathology. Berlin: Springer, 1990: 43-60.
51. Smith RRL, Hamilton SR, Boitnott JK, Rogers EL. The spectrum of carcinoma arising in Barrett's esophagus: a clinicopathologic study of 26 patients. Am J Surg Pathol 1984; 8: 563-73.
52. Streitz JM, Ellis FH, Gibb SP, Balogh K, Watkins E. Adenocarcinoma arising in Barrett's esophagus. A clinicopathologic study of 65 cases. Ann Surg 1991; 213: 122-5.
53. Haggitt RC, Tryzelaar J, Ellis FH, Colcher H. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol 1978; 70: 1-5.
54. Rosenberg JC, Budey H, Edwards RC, Singal S, Steiger Z, Sundareson AS. Analysis of adenocarcinoma in Barrett's esophagus utilizing a staging system. Cancer 1985; 55: 1353-60.
55. Harle IA, Finley RJ, Belsheim M, Bondy DC, Booth M, Lloyd D, et al. Management of adenocarcinoma in columnarlined esophagus. Ann Thorac Surg 1985; 40: 330-6.
56. De Baecque C, Potet F, Molas G, Fléjou JF, Barbier P, Martignon C. Superficial adenocarcinoma of the esophagus arising in Barrett's mucosa with dysplasia: a clinicopathological study of 12 patients. Histopathology 1990; 16: 213-20.
57. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992; 102: 1212-9.
58. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's esophagus. Gut 1991; 32: 1441-6.
59. Pera M, Trastek VF, Carpenter HA, Allen MS, Deschamps C, Pairolero PC. Barrett's esophagus with high grade dysplasia. An indication for esophagectomy? Ann Thorac Surg 1992; 54: 199-204.
60. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988; 19: 166-78.
61. Sagan C, Fléjou JF, Diebold MD, Potet F, Le Bodic MF. Reproductibilité des critères histologiques de dysplasie sur muqueuse de Barrett. Gastroenterol Clin Biol 1994; 18: D31-D34.
62. Neshat K, Sanchez CA, Galipeau PC, Levine DS, Reid BJ. Barrett's esophagus: the biology of neoplastic progression. Gastroenterol Clin Biol 1994; 18: D71-76.
63. Robaszkiewicz M, Hardy E, Volant A. Intérêt de l'analyse du contenu cellulaire en ADN par cytométrie en flux dans l'endobrachyœsophage. Gastroenterol Clin Biol 1994; 18: D35-D39.
64. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987; 93: 1-11.
65. Robaszkiewicz M, Hardy E, Volant A, Nousbaum JB, Cauvin JM, Calament G et al. Analyse du contenu cellulaire en ADN par cytométrie en flux dans les endobrachyœsophages: étude de 66 cas. Gastroenterol Clin Biol 1991; 15: 703-10.
66. Metges JP, Volant A, Hardy E, Cauvin JM, Nousbaum JB, Gouérou H et al. Bilan à 5 ans d'un programme de surveillance des endobrachyœsophages. Intérêt de l'analyse du contenu cellulaire en ADN par cytométrie en flux (abstract). Gastroenterol Clin Biol 1995; 19: A29.
67. Huang Y, Boynton RF, Blount PL, Silverstein RJ, Yin J, Tong Y et al. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 1992; 52: 6525-30.
68. Ferec C, Audrezet MP, Mercier B, Robaszkiewicz M. Les altérations du gène suppresseur de tumeur TP53 au cours de la transformation maligne de l'endobrachyœsophage. Gastroenterol Clin Biol 1994; 18: D46-D51.
69. Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PJ, et al. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 1991; 51: 5482-6.
70. Audrezet MP, Robaszkiewicz M, Mercier B, Nousbaum JB, Guillermit H, Volant A, et al. Etude des mutations du TP53 dans les adénocarcinomes sur endobrachyœsophage (abstract). Gastroenterol Clin Biol 1993; 17: A61.
71. Hamelin R, Fléjou JF, Muzeau F, Potet F, Laurent-Puig P, Fékété F et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994; 107: 1012-8.
72. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, Reid BJ. p53 mutations in Barrett's adenocarcinoma and high grade dysplasia. Gastroenterology 1994; 106: 1589-95.
73. Casson AG, Manolopoulos B, Troster M, Kerkvliet N, O'Malley F, Inculet R et al. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Am J Surg 1994; 167: 52-7.
74. Fléjou JF, Potet F, Muzeau F, Le Pelletier F, Fékété F, Hénin D. Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J Clin Pathol 1993; 46: 330-3.
75. Krishnadath KK, Mulder AH, Tilanus HW. p53 protein overexpression in Barrett's adenocarcinoma and Barrett's esophagus in paraffin-embedded tissue (abstract). Gastroenterology 1993; 104: A 1045
76. Hardwick EH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. Adenocarcinoma arising in Barrett's esophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 1994; 35: 764-8.
77. Symmans PJ, Linehan JM, Brito MJ, Filipe I. p53 expression in Barrett's oesophagus, dysplasia and adenocarcinoma using antibody D0-7. J Pathol 1994; 173: 221-6.
78. Rice TW, Goldblum JR, Falk GW, Tubbs RR, Kirby TJ, Casey G. p53 immunoreactivity in Barrett's metaplasia, dysplasia and carcinoma. Thorac Cardiovasc Surg 1994; 108: 1132-7.
79. Ramel S, Reid BJ, Sanchez CA, Blount PL, Levine DS, Neshat K, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 1992; 102: 1220-8.
80. Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia and carcinoma: a follow-up study. Gastroenterology 1993; 105: 1637-42.
81. Fléjou JF, Volant A, Diebold MD, Sagan C, Vissuzaine C, Croué A, et al. Surexpression de la protéine p53 et endobrachyœsophage: un événement fréquent et précoce au cours de la carcinogenèse. Gastroenterol Clin Biol 1995; 19: 475-81.
82. Jones DR, Davidson AG, Summers CL, Murray GF, Quinlan DC. Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Ann Thorac Surg 1994; 57: 598-603.
83. Levine DS. Barrett's esophagus and p53. Lancet 1994; 344: 212-3.
84. Garewal HS, Sampliner R, Gerner E, Steinbronn K, Alberts D, Kendall D. Ornithine decarboxylase activity in Barrett's esophagus a potential marker for dysplasia. Gastroenterology 1988; 94: 819-21.
85. Gray MR, Wallace HM, Goulding H, Hoffman J, Kenyon WE, Kingsnorth AN. Mucosal polyamine metabolism in the columnar lined esophagus. Gut 1993; 34: 584-7.
86. Gray MR, Hall PA, Nash J, Ansari B, Lane DP, Kingsnorth AN. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 1992; 103: 1769-76.
87. Jankowski J, Mc Menemin, Yu C, Hopwood D, Wormsley KG. Proliferating cell nuclear antigen in œsophageal diseases; correlation with transforming growth factor alpha expression. Gut 1992; 33: 587-91.
88. Gillen P, Mc Dermott M, Grehan D, Hourihane OB, Hennessy TPJ. Proliferating cell nuclear antigen in the assessment of Barrett's mucosa. Br J Surg 1994; 81: 1766-8.
89. Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993; 105: 119-29.
90. Iftikhar SY, Steele RJC, Watson S, James PD, Dilks K, Hardcastle JD. Assessment of proliferation of squamous, Barrett's and gastric mucosa in patients with columnar lined Barrett's œsophagus. Gut 1992; 33: 733-7.
91. Hong MK, Laskin WB, Herman BE, Johnston MH, Vargo JJ, Steinberg SM et al. Expansion of the Ki67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer 1995; 75: 423-9.
92. Jankowski J. Altered expression of growth factors and their receptors during esophageal tumorigenesis. Gastroenterol Clin Biol 1994; 18: D40-45.
93. Jankowski J, Hoppwood D, Pringle R, Wormsley KG. Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis. Am J Gastroenterol 1993; 88: 402-8.
94. Poller DN, Steele RJC, Morrell K. Epidermal growth factor receptor expression in Barrett's esophagus. Arch Pathol Lab Med 1992; 116: 1226-7.
95. Abdelatif OMA, Chandler FW, Mills LR, Mc Guire BS, Pantazis CG, Barrett JM. Differential expression of c-myc and H-ras oncogenes in Barrett's epithelium. A study using colorimetric in situ hybridization. Arch Pathol Lab Med 1991; 115: 880-5.
96. Altorki NK, Sunagawa M, Little AG, Skinner DB. High grade dysplasia in the columnar-lined esophagus. Am J Surg 1991; 161: 97-100
97. Hamilton SR, Smith RRL. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol 1987: 87: 301-12.
98. Streitz JM, Andrews CW, Ellis FH. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993; 105: 383-88.
99. Naef AP, Savary M, Ozello L. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. J Thorac Cardiovasc Surg 1975; 70: 826-35.
100. Riddell RH. Screening strategies in gastrointestinal cancer. Scand J Gastroenterol 1990; 25 (suppl 175): 177-84.
101. Falk GW, Catalano MF, Sivak MV Jr, Rice TW, Van Dam J. Endosonography in the evaluation of patients with Barrett's esophagus and high grade dysplasia. Gastrointest Endosc 1994; 40: 207-12.
102. Rusch VW, Levine DS, Haggitt R, Reid BJ. The management of high grade dysplasia and early cancer in Barrett's esophagus. Cancer 1994; 1225-9.
103. Frémond L, Bouché O, Diébold MD, Demange L, Zeitoun P, Thiefin G. Régression partielle d'un endobrachyœsophage en dysplasie de haut grade avec adénocarcinome après photoco-agulation et endocuriethérapie sous traitement antisécrétoire. Gastroenterol Clin Biol 1995; 19: 112-6.
104. Overholt B, Panjehpour M, Tefftellar E, Rose M. Photodynomic therapy for treatment of early adenocarcinoma in Barrett's esophagus. Gastrointest Endosc 1993; 39: 73-6.
105. Berenson MM, Johnson TD, Markowitz NA, Buchi KN, Samowitz WS. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology 1993; 104: 1686-91.
106. Le Rhun M, Galmiche JP. La régression de l'endobrachyœsophage est-elle possible? Gastroenterol Clin Biol 1994; 18: D17-D22.
107. Williamson WA, Ellis FH, Gibb SP, Shahian DM, Aretz HT. Effect of antireflux operation on Barrett's mucosa. Ann Thorac Surg 1990; 49: 537-42.
108. Fléjou JF, Paraf F, Potet F, Fékété F. Le cancer superficiel sur endobrachyœsophage. Gastroenterol Clin Biol 1994; 18: D59-D62.
109. Fléjou JF, Paraf F, Potet F, Fékété F. Les facteurs pronostiques du cancer sur endobrachyœsophage. Gastroenterol Clin Biol 1994; 18: D63-D66.
110. Peters JH, Clark GWB, Ireland AP, Chaudrasoma P, Smyrk TC, De Meester TR. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108: 813-22.
111. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 670-80.